Complete response in patient with liver metastasis of HER2-positive breast cancer following therapy with margetuximab: a case report

被引:1
|
作者
Chang, Haiyan [1 ]
Hu, Ting [1 ]
Hu, Jie [1 ]
Ding, Teng [2 ]
Wang, Qiong [1 ,3 ]
Cheng, Jing [1 ]
机构
[1] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Oncol, Wuhan, Peoples R China
[2] Zai Lab Shanghai Co Ltd, Med Affairs Dept, Shanghai, Peoples R China
[3] Huazhong Univ Sci & Technol, Dept Oncol, Union Hosp, Tongji Med Coll, 109 Machang Rd, Wuhan, Hubei, Peoples R China
关键词
breast cancer; human epidermal growth factor receptor 2; liver metastasis; margetuximab; TRASTUZUMAB; POLYMORPHISMS; BENEFIT;
D O I
10.1097/CAD.0000000000001466
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic human epidermal growth factor receptor 2 (HER2) positive breast cancer has a poor prognosis and few effective targeted therapies. However, several anti-HER2 agents are emerging in conjunction with chemotherapy, which may lead to increased rates of pathological complete response in patients with HER2-positive metastatic breast cancer. Among them, margetuximab demonstrated a significant improvement in progression-free survival compared with trastuzumab, when combined with chemotherapy in pretreated patients. Here we present a case of a 67-year-old female patient who was diagnosed with HER2-positive, histological grade III and invasive ductal carcinoma of the left breast in September 2018. She received postoperative adjuvant therapy with EC-TH plus radiotherapy, followed by therapy with HER2-targeted trastuzumab for 1 year (till December 2019). In May 2020, routine reexamination showed a supraclavicular lymph node and bone metastasis. Patient was then treated with pyrotinib, capecitabine and bisphosphonate for a period of 3 months. In December 2020, liver MRI revealed multiple liver metastases. The patient received eight cycles of second-line therapy (vinorelbine plus margetuximab) from January 2021. Since the ninth cycle, the patient was continued with only margetuximab. In March 2021, MRI showed a 70% decrease in the liver metastasis lesions. By June 2021, liver lesions were totally disappeared. During therapy, patient experienced only grade-1 anemia. This case demonstrates that margetuximab plus chemotherapy is safe and might bring clinical benefits for patients with HER2-positive breast cancer with liver metastasis. Further studies evaluating the efficacy and safety of margetuximab in Chinese HER2-positive breast cancer patients are needed.
引用
收藏
页码:883 / 887
页数:5
相关论文
共 50 条
  • [11] Margetuximab: An active alternative for later-line therapy in patients with HER2-positive advanced breast cancer
    Zhou, Yunxiang
    Wang, Xiaojia
    Chen, Yiding
    MEDCOMM, 2023, 4 (04):
  • [12] Case report of duration of response in HER2-positive NSCLC patient
    Bangieva-Ivanova, Elena
    Ivanov, Hristo
    Stoyanova, Vili
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2024, 32 : 261 - 262
  • [13] A Case of Corneal Melting in a Patient with HER2-Positive Breast Cancer
    Peeters, Deborah
    Vereecken, Melissa
    Denys, Hannelore
    Roels, Dimitri
    CASE REPORTS IN OPHTHALMOLOGY, 2022, 13 (03): : 1036 - 1041
  • [14] Prolonged survival in a patient with metastatic HER2-positive inflammatory breast cancer: A case report
    Xia, Yu
    Luo, Jing
    ASIAN JOURNAL OF SURGERY, 2024, 47 (11) : 4934 - 4936
  • [15] Pure mucinous breast cancer HER2-positive, a case report
    Gonzalez Aranda, A. M.
    Martinez Gomez, E.
    Santana Costa, A.
    Arnanz Velasco, F.
    Gonzalez de Diego, M. H.
    Zapico Goni, A.
    CLINICA E INVESTIGACION EN GINECOLOGIA Y OBSTETRICIA, 2021, 48 (04):
  • [16] Sarcoid-like reaction in a HER2-positive breast cancer patient: A case report
    Sekine, Chikako
    Kawase, Kazumi
    Yoshida, Kazuhiko
    INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS, 2021, 85
  • [17] A Review of Margetuximab-Based Therapies in Patients with HER2-Positive Metastatic Breast Cancer
    Alasmari, Moudi M.
    CANCERS, 2023, 15 (01)
  • [18] Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer
    Schlam, Ilana
    Nunes, Raquel
    Lynce, Filipa
    ONCOTARGETS AND THERAPY, 2022, 15 : 471 - 478
  • [19] Appendicitis caused by the metastasis of HER2-positive breast cancer
    Mori, Ryutaro
    Futamura, Manabu
    Morimitsu, Kasumi
    Yoshida, Kazuhiro
    SURGICAL CASE REPORTS, 2016, 2
  • [20] Appendicitis caused by the metastasis of HER2-positive breast cancer
    Ryutaro Mori
    Manabu Futamura
    Kasumi Morimitsu
    Kazuhiro Yoshida
    Surgical Case Reports, 2 (1)